Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.

ImmunoHorizons - 25 Aug 2021

Izumi Kiyotaka, Shindo Takero, Ngo Huong Thi, Nakayama-Hosoya Kaori, Akahane Koshi, Tamai Minori, Nguyen Thao T T, Kawana-Tachikawa Ai, Inukai Takeshi, Takaori-Kondo Akifumi

Abstract excerpt

Tyrosine kinase inhibitor (TKI)-treated chronic myeloid leukemia (CML) patients with increased NK cell number have a better prognosis, and thus, NK cells may suppress CML. However, the efficacy of TKIs varies for reasons yet to be fully elucidated. As NK cell activity is modulated by interactions between their killer cell Ig-like receptors (KIRs) and HLAs of target cells, the combination of their polymorphisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytotoxicity, Immunologic
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Gene Expression Regulation, Leukemic

Share to K562 Cells

Share to Killer Cells, Natural

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Receptors, KIR3DL1

Source

Identifiers

PMID: 34433624
DOI: 10.4049/immunohorizons.2100054

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.PMID 34433624Read ↗

Activating KIR3DS1: A key driver of KIR3DL1/HLA-Bw4-linked risk in CML.Semantic proximity Read ↗

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia.Semantic proximity Read ↗

Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML.Semantic proximity Read ↗

KIR2DS3 is associated with protection against acute myeloid leukemia.Semantic proximity Read ↗

Identification of natural killer cell receptor phenotypes associated with leukemia.Semantic proximity Read ↗

KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.Semantic proximity Read ↗

Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells.Semantic proximity Read ↗

Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cellsSemantic proximity Read ↗

HLA alleles determine differences in human natural killer cell responsiveness and potency.Semantic proximity Read ↗

Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical ExploitationSemantic proximity Read ↗

Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cellsSemantic proximity Read ↗

High-Risk Leukemia: Past, Present, and Future Role of NK CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.